Emanita Mounga
Family · West Valley, UTNPI 1306322441
Payments from drug & device makers
Across 183 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$655
- AbbVie$652
- Novo Nordisk$477
- GSK$461
- Braeburn Inc.$288
- Lilly USA, LLC$232
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,73298%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 29 | $655 |
| AbbVie | 40 | $652 |
| Novo Nordisk | 18 | $477 |
| GSK | 10 | $461 |
| Braeburn Inc. | 4 | $288 |
| Lilly USA, LLC | 10 | $232 |
| Boehringer Ingelheim | 10 | $213 |
| Edwards Lifesciences | 1 | $202 |
| Boston Scientific | 7 | $197 |
| Corcept Therapeutics | 3 | $179 |
| Phathom Pharmaceuticals, Inc. | 2 | $137 |
| Astellas Pharma US Inc | 3 | $133 |
| Lucid Diagnostics Inc. | 3 | $132 |
| AstraZeneca | 8 | $127 |
| Merck | 4 | $116 |
| Alkermes, Inc. | 1 | $73 |
| Inspire Medical Systems, Inc. | 1 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $59 |
| Pfizer | 4 | $55 |
| Cranial Technologies, Inc | 3 | $53 |
| Johnson & Johnson | 2 | $40 |
| Seqirus USA Inc | 2 | $39 |
| Shield Therapeutics Inc | 1 | $32 |
| Lundbeck LLC | 1 | $29 |
| Organon | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Viiv Healthcare Company | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,826 in reported general payments places this provider in the 90th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 82 | $81,843 |
| OzempicSemaglutide | 47 | $51,839 |
| EliquisApixaban | 51 | $41,001 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $28,724 |
| JardianceEmpagliflozin | 18 | $22,367 |
| JanuviaSitagliptin Phosphate | 16 | $20,484 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $14,004 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $9,546 |
| MyrbetriqMirabegron | 11 | $9,499 |
| Atrovent HfaIpratropium Bromide | 15 | $7,036 |
| FetzimaLevomilnacipran Hcl | 12 | $6,394 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,634 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,807 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,899 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $3,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $127 | $110,567118 claims |
| Novo NordiskOzempic | $477 | $51,83947 claims |
| PfizerEliquis | $55 | $41,00151 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $213 | $28,00130 claims |
| MerckJanuvia | $116 | $20,48416 claims |
| Astellas Pharma US IncMyrbetriq | $133 | $9,49911 claims |
| AbbVieFetzima | $652 | $6,39412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,460 family providers in Utah.
Other family in West Valley
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.